Regular intake of Wobenzym® may prevent late complications in diabetes mellitus
Dzivite I.1, Sochnevs A.2,
Stauder G.3, Zeibarts M.4, Lauga U.4,
Ansbergs J.5. Regular intake of Wobenzym® may prevent
late complications in diabetes mellitus. Int. J. Immunotherapy 2001,
Vol. XVII, No. 2/3/4, pp. 143-148- ISSN 0255-9625 218 K/375
(19-05-3)
1) Children’s and Teenagers’ Endocrinology Center, Bernu Kliniska
University Slimnica, Pediatric University Hospital, Riga, Latvia. 2)
Institute of Immunology, Riga Stradins University and Latvian
Medical Academy, Riga, Latvia. 3) Clinical Research, MUCOS Pharma,
Geretsried, Germany. 4) Riga Stradins University and Latvian Medical
Academy, Riga, Latvia. 5) MUCOS-Balt Ltd., Riga, Latvia.
Summary: In this observational study, the results of a 12-month treatment of two groups of children, aged 4-18 years, with newly diagnosed type 1 diabetes were compared. Half of the patients received insulin preparation only, while the other half was treated with the combination of a similar insulin preparation and Wobenzym®. At the start of therapy, the mean values of all laboratory indices were similar in both groups of children. A difference between mean HbA1c levels in both groups was observed at the first follow-up (p = 0.0179). During treatment, further differences became highly significant in favor of the enzyme group (p <0.0001). After 12 months, higher levels of C-peptide were found in children treated with Wobenzym® (p = 0.0012). At the start of therapy there were no differences between the groups of children in the dosage of insulin used. However, from the first follow-up visit, greater amounts of insulin were used in the control group. The difference between circulating immune complexes (CIC) levels at the start and end of therapy was also significant in favor of the enzyme group (p = 0.0018). Enzyme therapy caused no undesirable adverse effects. Based on the results obtained, Wobenzym® can be assumed to decrease the activity of the inflammatory process and support a restitution of pancreatic b-cells. This may explain the improved metabolic compensation found in patients who received Wobenzym®. We suggest that regular intake of Wobenzym® together with individually adjusted insulin therapy can prevent the development of late pathological outcomes in diabetes.